REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
This article is part of the Research TopicExploring Unconventional T Cells and CAR-T-Cells in Cancer ImmunotherapyView all 10 articles
The new era of immunotherapy for breast cancer: challenges and coping strategies of CAR-T cell therapy
Provisionally accepted
- Department of Thyroid and Breast Surgery, Jining First People's Hospital, Jining, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Breast cancer remains the most prevalent malignant tumor among women globally, with persistently high incidence and mortality rates. Despite the diversity of existing treatment modalities, systemic therapies for advanced, metastatic, and triple-negative breast cancer continue to face significant limitations. Recently, chimeric antigen receptor T (CAR-T) cell therapy has demonstrated considerable success in the treatment of hematological malignancies, offering a novel approach for breast cancer treatment. This paper reviews the primary targets and research advancements of CAR-T cells in breast cancer therapy, while also analyzing current challenges such as immunosuppression within the tumor microenvironment, antigen heterogeneity, obstacles in cell homing, and the limited durability of CAR-T cells. Furthermore, strategies to address these challenges are discussed. Although CAR-T cell therapy for breast cancer is still in the nascent stages of exploration, ongoing technological advancements and in-depth research hold promise for its potential as a novel therapeutic option, thereby offering renewed hope to patients.
Keywords: breast cancer, Immunotherapy, CAR-T cells, challenge, coping strategy
Received: 03 Sep 2025; Accepted: 17 Nov 2025.
Copyright: © 2025 Wang, Miao and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Lele Miao, miaoll19@lzu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.